Geron | GERN - Selling And Administration Expenses


Geron reported $41.67M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Amgen USD 1.94B 237M Dec/2025
Bio Techne USD 113.69M 2.52M Dec/2025
Cassava Sciences USD 6.66M 1.24M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Genmab DKK 208M 60M Dec/2025
Geron USD 41.67M 2.67M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025